• Facebook
  • X
  • Instagram
  • Contact Us
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

NCCN Cancer Experts Answer Questions about COVID-19 Vaccines

by MM360 Staff | Jun 10, 2021 | Uncategorized

(NCCN) June 10, 2021 – National Comprehensive Cancer Network’s patient information team provides a patient and caregiver version of recently-updated, evidence-based expert consensus recommendations for vaccinating people with cancer against COVID-19.

Cutting-Edge Test Detects Early Tumor Recurrence In Some Cancers

by MM360 Staff | Jun 10, 2021 | Uncategorized

(ABC News/Good Morning America) June 10, 2021 – A new blood test seeks to change the game in cancer management.

Asco 2021 Movers – PDS Wins, But Big Pharma Reigns

by MM360 Staff | Jun 10, 2021 | Uncategorized

(Evaluate Vantage) June 9, 2021 – PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.

ALX Oncology to Collaborate with Lilly to Evaluate ALX148 Plus CYRAMZA® (Ramucirumab), Trastuzumab, and Paclitaxel in Patients with Gastric or Gastroesophageal Junction Cancer

by MM360 Staff | Jun 10, 2021 | Uncategorized

(Yahoo! Finance) June 10, 2021 – ALX Oncology, a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and...

Cardinal Health™ Nuclear & Precision Health Solutions Receives U.S. Food and Drug Administration Approval for New LYMPHOSEEK® Pediatric Indication

by MM360 Staff | Jun 10, 2021 | Uncategorized

(Cardinal Health) June 10, 2021 – The new indication will provide accurate and precise lymph node identification in pediatric patients one month and older with melanoma, rhabdomyosarcoma or other types of solid tumors.
« Older Entries
Next Entries »

Recent Content

  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
  • A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
  • Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
  • Triplet regimen extends OS in relapsed or refractory multiple myeloma
  • Contact Us
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT